Is VIR or VKTX more undervalued in 2026?

CirclFi compares Vir Biotechnology, Inc. (VIR) and Viking Therapeutics, Inc. (VKTX) using 13 institutional-grade valuation models. VIR has a Quality of Company score of 7.0/10 while VKTX scores 4.7/10.

Which is a better buy — VIR or VKTX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do VIR and VKTX valuations compare?

VIR at $9.55 and VKTX at $32.19 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

VIR vs VKTX Valuation Comparison 2026 — Intrinsic Value Analysis

VIR

Biotechnology

Vir Biotechnology, Inc.

Quality

7.0

out of 10

Value Trap

SAFE

Price

$9.55

Last close

Models

11/13

Active

VKTX

Biotechnology

Viking Therapeutics, Inc.

Quality

4.7

out of 10

Value Trap

SAFE

Price

$32.19

Last close

Models

10/13

Active

Model-by-Model Comparison

Model	Type	VIR Fair Value	VIR Upside	VKTX Fair Value	VKTX Upside
Bayesian DCF	Intrinsic	$2.52	-73.6%	$10.25	-68.1%
Earnings Power Value	Intrinsic	$5.74	-42.6%	$14.75	-55.0%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for VIR vs VKTX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

VIR vs VKTX — Which Stock Is More Undervalued?

VIR scores higher with a 7.0/10 quality rating vs VKTX's 4.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Vir Biotechnology, Inc. (VIR) and Viking Therapeutics, Inc. (VKTX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

VIR currently trades at $9.55 with a QOC of 7.0/10, while VKTX trades at $32.19 with a QOC of 4.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).